Articles from Stevanato Group

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET).

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule and biologic therapies, enabling treatment for conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain management.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant.

Stevanato Group (NYSESTVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, announced today that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor Business Media.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will livestream its inaugural Capital Markets Day on September 27, 2023 from 11:00 a.m. ET to approximately 2:30 p.m. ET.

Stevanato Group S.p.A. (NYSESTVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion.

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it has published the agenda for the 2022 Annual General Meeting of Shareholders (“AGM”), which will be held virtually on June 1, 2022, beginning at 4:00 p.m. (CEST) / 10:00 a.m. (EDT).

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D™ pen injector technology.

Stevanato Group (NYSESTVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company.

Stevanato Group S.p.A. (NYSESTVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter 2021.

Stevanato Group (NYSESTVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has been recognized as a winner of Pharma Manufacturing magazine’s 2021 Pharma Innovation Award for its AI-ready Vision Robot Unit (VRU) - a robotic human-like inspection unit.

Stevanato Group (NYSESTVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an additional supply source for its mission critical products to serve customers better.